J2 Capital Management Inc Invests $521,000 in Medpace Holdings, Inc. $MEDP

J2 Capital Management Inc bought a new stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 1,086 shares of the company’s stock, valued at approximately $521,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Optiver Holding B.V. bought a new position in Medpace during the third quarter valued at $27,000. Steigerwald Gordon & Koch Inc. purchased a new position in shares of Medpace in the 4th quarter worth $30,000. Elyxium Wealth LLC bought a new stake in shares of Medpace in the 4th quarter worth about $30,000. Quarry LP bought a new stake in shares of Medpace in the 3rd quarter worth about $35,000. Finally, Bayban bought a new stake in shares of Medpace in the 4th quarter worth about $44,000. 77.98% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other Medpace news, General Counsel Stephen P. Ewald sold 16,349 shares of the business’s stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the completion of the transaction, the general counsel owned 20,343 shares in the company, valued at $9,154,350. The trade was a 44.56% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 20.50% of the stock is owned by company insiders.

Medpace Trading Up 1.4%

Medpace stock opened at $519.96 on Friday. The firm has a 50-day moving average price of $451.02 and a 200-day moving average price of $496.81. The firm has a market capitalization of $14.85 billion, a PE ratio of 32.68, a price-to-earnings-growth ratio of 2.60 and a beta of 1.18. Medpace Holdings, Inc. has a 12-month low of $305.69 and a 12-month high of $628.92.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Wednesday, April 22nd. The company reported $4.28 EPS for the quarter, topping analysts’ consensus estimates of $3.74 by $0.54. Medpace had a net margin of 17.19% and a return on equity of 120.89%. The firm had revenue of $706.60 million during the quarter, compared to analysts’ expectations of $697.82 million. During the same period in the previous year, the company earned $3.67 EPS. The firm’s revenue for the quarter was up 26.5% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, sell-side analysts predict that Medpace Holdings, Inc. will post 17.04 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on MEDP. BMO Capital Markets lowered their price target on shares of Medpace from $460.00 to $400.00 and set a “market perform” rating for the company in a report on Friday, April 24th. Weiss Ratings cut Medpace from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday, April 6th. Barclays lowered their price objective on Medpace from $500.00 to $450.00 and set an “equal weight” rating for the company in a research note on Friday, April 24th. Wall Street Zen cut Medpace from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Finally, Royal Bank Of Canada cut their target price on Medpace from $522.00 to $484.00 and set an “outperform” rating on the stock in a research report on Friday, April 24th. Four equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $467.08.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.